{"id":1,"action":"create","user":"Admin","created_at":"2015-04-02T15:01:22.650Z","changes":{"entrez_id":238,"name":"ALK","description":"ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.","official_name":"anaplastic lymphoma receptor tyrosine kinase","clinical_description":null},"diffs":{"entrez_id":"\u003cdiv class=\"diff\"\u003e\n  \u003cul\u003e\n    \u003cli class=\"del\"\u003e\u003cdel\u003e238\u003c/del\u003e\u003c/li\u003e\n  \u003c/ul\u003e\n\u003c/div\u003e\n","name":"\u003cdiv class=\"diff\"\u003e\n  \u003cul\u003e\n    \u003cli class=\"del\"\u003e\u003cdel\u003eALK\u003c/del\u003e\u003c/li\u003e\n  \u003c/ul\u003e\n\u003c/div\u003e\n","description":"\u003cdiv class=\"diff\"\u003e\n  \u003cul\u003e\n    \u003cli class=\"del\"\u003e\u003cdel\u003eALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI\u0026#39;s have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.\u003c/del\u003e\u003c/li\u003e\n  \u003c/ul\u003e\n\u003c/div\u003e\n","official_name":"\u003cdiv class=\"diff\"\u003e\n  \u003cul\u003e\n    \u003cli class=\"del\"\u003e\u003cdel\u003eanaplastic lymphoma receptor tyrosine kinase\u003c/del\u003e\u003c/li\u003e\n  \u003c/ul\u003e\n\u003c/div\u003e\n","clinical_description":"\u003cdiv class=\"diff\"\u003e\u003c/div\u003e"}}